Crystal Structure of the TLR1-TLR2 Heterodimer Induced by Binding of a Tri-Acylated Lipopeptide  by Jin, Mi Sun et al.
Crystal Structure of the TLR1-TLR2
Heterodimer Induced by Binding
of a Tri-Acylated Lipopeptide
Mi Sun Jin,1 Sung Eun Kim,1,4 Jin Young Heo,1,4 Mi Eun Lee,1 Ho Min Kim,1 Sang-Gi Paik,3 Hayyoung Lee,3
and Jie-Oh Lee1,2,*
1Department of Chemistry
2Institute for Bio-Century
Korea Advanced Institute of Science and Technology, Daejon, Korea 305-701
3Department of Biology, School of Bioscience & Biotechnology, Chungnam National University, Daejon, Korea 305-764
4These authors contributed equally to this work.
*Correspondence: jieoh.lee@kaist.ac.kr
DOI 10.1016/j.cell.2007.09.008SUMMARY
TLR2 in association with TLR1 or TLR6 plays an
important role in the innate immune response
by recognizing microbial lipoproteins and lipo-
peptides. Here we present the crystal struc-
tures of the human TLR1-TLR2-lipopeptide
complex and of the mouse TLR2-lipopeptide
complex. Binding of the tri-acylated lipopep-
tide, Pam3CSK4, induced the formation of an
‘‘m’’ shaped heterodimer of the TLR1 and
TLR2 ectodomains whereas binding of the di-
acylated lipopeptide, Pam2CSK4, did not. The
three lipid chains of Pam3CSK4mediate the het-
erodimerization of the receptor; the two ester-
bound lipid chains are inserted into a pocket
in TLR2, while the amide-bound lipid chain is
inserted into a hydrophobic channel in TLR1.
An extensive hydrogen-bonding network, as
well as hydrophobic interactions, between
TLR1 and TLR2 further stabilize the hetero-
dimer. We propose that formation of the
TLR1-TLR2 heterodimer brings the intracellular
TIR domains close to each other to promote di-
merization and initiate signaling.
INTRODUCTION
Toll-like receptor (TLR) family proteins play a crucial role in
innate immunity by recognizing conserved patterns in di-
verse microbial molecules including lipoproteins, lipopep-
tides, lipopolysaccharide, flagellin, and nucleic acids
(Akira and Takeda, 2004; West et al., 2006). TLRs are
type I transmembrane glycoproteins with a single trans-
membrane domain and a conserved intracellular domain
(Akira and Takeda, 2004; West et al., 2006). The extracel-Cell 1lular domains of TLRs have 16 to 28 LRR modules (Mat-
sushima et al., 2007). The LRR modules have 2030
amino acid residues with conserved ‘‘LxxLxLxxN’’ motifs
(Kajava, 1998; Kobe and Kajava, 2001). Binding of ligands
to the extracellular domains of TLRs causes rearrange-
ment of the receptor complexes and triggers the recruit-
ment of specific adaptor proteins to the intracellular TIR
domains (O’Neill and Bowie, 2007).
TLR2 in association with TLR1 or TLR6 is essential for
recognizing bacterial lipoproteins and lipopeptides (Take-
uchi et al., 2001, 2002). These lipoproteins are anchored to
the cell membrane via conserved N termini modified by
lipid chains (Chambaud et al., 1999) and induce strong
proinflammatory signals in macrophages (Henderson
et al., 1996). TLR2-deficient mice do not respond to the li-
poproteins and are more susceptible to septicemia due to
S. aureus, meningitis due to S. pneumoniae and L. mono-
cytogenes, and infection with M. tuberculosis (Echchan-
naoui et al., 2002; Sugawara et al., 2003; Takeuchi et al.,
2000). Human TLR2 with the Arg753Gln polymorphism is
significantly less responsive to bacterial lipoproteins de-
rived from B. burgdorferi, T. pallidum, andM. tuberculosis
(Lorenz et al., 2000; Ogus et al., 2004). Twenty-two per-
cent of Lepromatous leprosy patients have an Arg to Trp
substitution at amino acid residue 677 of TLR2 that
abolishes activation of NF-kB in response to M. leprae
and M. tuberculosis (Bochud et al., 2003; Kang and
Chae, 2001). Therefore TLR2 plays an indispensable role
in lipoprotein-induced inflammatory responses.
Most bacterial lipoproteins contain conserved tri-
acylated cysteines at their N termini except mycoplasmal
lipopeptides such as MALP2 and FSL-1 that contain
di-acylated cysteines (Hantke and Braun, 1973; Mu¨hlradt
et al., 1997; Shibata et al., 2000). In the tri-acylated lipo-
proteins, the di-acylated glyceryl group is attached to
the N-terminal cysteine via a thioether bond and the third
lipid chain is connected to the cysteine via an amide bond.
The mycoplasmal di-acylated lipopeptides lack the
amide-bound lipid chain. Palmitoyl groups are the most30, 1071–1082, September 21, 2007 ª2007 Elsevier Inc. 1071
common lipid chains in the bacterial lipoproteins but other
lipid chains are also found (Belisle et al., 1994; Braun,
1975; Mizuno, 1979; Zlotnick et al., 1988). Synthetic lipo-
peptide analogs containing di- or tri-acylated cysteine
groups mimic the proinflammatory properties of lipopro-
teins, thus confirming that the acylated N-terminal cyste-
ine is the principal immune stimulatory motif (Berg et al.,
1994; Bessler et al., 1985; Seifert et al., 1990; Wiesmu¨ller
et al., 1992). TLR2 is essential for both tri- and di-acylated
lipopeptide responses whereas TLR1 and TLR6 are
required for recognition of the tri- and di-acylated lipopep-
tides, respectively (Alexopoulou et al., 2002; Buwitt-Beck-
mann et al., 2006; Morr et al., 2002; Ozinsky et al., 2000;
Takeuchi et al., 2001, 2002). Therefore it has been postu-
lated that TLR2 complexeswith TLR1 or TLR6 are involved
in the recognition of bacterial lipoproteins (Akira and
Takeda, 2004; Gay and Gangloff, 2007; West et al., 2006).
Ligand-induced multimerization has been proposed as
a key event in the activation of several TLRs. However,
the structures of the TLRmultimers have not been studied
in atomic detail. Furthermore, no structure of a TLR inter-
acting with an agonistic ligand is yet available. To provide
this information we undertook structural studies of TLR2
and its complexes with lipopeptide ligands and TLR1.
The structure shows that binding of the tri-acylated lipo-
peptide, Pam3CSK4, induced the formation of an ‘‘m’’
shaped heterodimer of the TLR1 and TLR2 that closely re-
sembles the model of the ligand-induced TLR4-MD-2 het-
erotetramer recently proposed by us (Kim et al., 2007b).
RESULTS
Structure Determination of the TLR1-TLR2-
Lipopeptide Complex
To facilitate the production and crystallization of human
TLR1 and TLR2, we used the Hybrid LRR Technique as
previously described (Kim et al., 2007b). For this, frag-
ments of TLR and hagfish VLRB.61 were fused at their
conserved ‘‘LxxLxLxxN’’ sites while the relative positions
of the conserved leucines and asparagines were strictly
preserved (Tables S1–S4). VLRB.61 is a clone of the hag-
fish Variable Lymphocyte Receptors (VLRs) (Kim et al.,
2007a; Pancer and Cooper, 2006). Thirty-three out of
sixty-two hybrids tested could be produced as soluble
proteins. As shown previously (Kim et al., 2007b), most
of the hybrids that failed to produce soluble proteins ap-
pear either to form atomic collisions or to expose hydro-
phobic cores at the fusion sites. Among the soluble hy-
brids, shorter TLR2 hybrids that do not include the
ligand-binding and dimerization regions failed to bind to
both Pam2CSK4 and Pam3CSK4 lipopeptides (Figure 1
and Tables S1–S4). Therefore hybrids with longer TLR2
fragments, hT2V7, hT2V8, and hT2V9, were tested for li-
gand binding and heterodimer formation. They all formed
stable heterodimers with a TLR1 hybrid, hT1V8, after bind-
ing of Pam3CSK4. Among them, the Pam3CSK4-induced
heterodimer of hT1V8 and hT2V9 was successfully crystal-
lized for structure analysis. The hT1V8 hybrid was used as1072 Cell 130, 1071–1082, September 21, 2007 ª2007 Elsevierthe binding partner because it is the second longest TLR1
hybrid and could be produced in a quantity large enough
for crystallographic study. Pam2CSK4 did not induce het-
erodimerzation of TLR1 and TLR2. In hT1V8 and hT2V9,
the C-terminal 105 amino acids of the ectodomain of hu-
man TLR1 and the 82 amino acids of the ectodomain of
TLR2, respectively, were replaced with fragments of hag-
fish VLRB.61. The hT1V8-hT2V9-Pam3CSK4 complex was
stable and could not be separated by gel filtration chroma-
tography, and fractions containing the complex were
concentrated and crystallized for structure determination.
The crystallized complex contains a single Pam3CSK4
ligand shared by the TLR1 and TLR2 hybrids (Figure 2).
Two of the three lipid chains of the ligand interact with
a pocket in TLR2, and the remaining amide-bound lipid
chain is inserted into a narrow channel in TLR1. The
TLR1 channel and TLR2 pocket are connected at the di-
mer interface, forming a long and continuous lipid-binding
site. The overall shape of the complex resembles the letter
‘‘m’’ where the two C-terminal domains converge in the
middle. The TLR1-fused and TLR2-fused VLR fragments
in the complex do not interact with each other or with
the TLR fragments since their closest atoms are more
than 9 A˚ apart. As shown for the TLR4-VLR hybrids in
the previous report (Kim et al., 2007b), the fusion of
TLR1/2 and VLR did not induce significant structural
changes in either the VLR or the TLRs, further confirming
the utility of the Hybrid LRR method for structure studies
of LRR proteins (see Supplemental Discussion).
Figure 1. Crystallized TLR-VLR Hybrid Proteins
Full-length and VLR hybrids of TLR1 (A) and TLR2 (B) are represented
schematically. TLR1 and TLR2 and hagfish VLRB.61 are shown in
green, blue, and white boxes, respectively. The ligand-binding and di-
merization domains were identified from our crystal structure. Amino
acid sequences at the fusion boundaries and the corresponding con-
served patterns are given underneath the boxes. The sequenceswithin
the parentheses are non-native sequences from the cloning sites.Inc.
Figure 2. Overall Structure of the Human
TLR1-TLR2-Pam3CSK4 Complex
The TLR1 fragments in the hT1V8 hybrid, the
TLR2 fragments in hT2V9 hybrid, and the
VLRB.61 fragments are shown schematically
in green, blue, and gray, respectively. The cen-
tral domains are colored in light green or light
blue, and the Pam3CSK4 lipopeptide in red.
Disulfide bridges are represented as yellow
lines. Domains belonging to the TLR1 hybrid
proteins are labeled with apostrophes. (A)
side view; (B) top view.Since the hT1V8, hT2V9, and mT2V6 hybrids contain
most of the TLR ectodomains and all the functionally
important amino acid residues (see below), we refer to
them as ectodomains of human TLR1, human TLR2, and
mouse TLR2, respectively, in this article (Figure 1).
Structures of TLR1 and TLR2 in the TLR1-TLR2-
Lipopeptide Complex
Like TLR4 but not TLR3, TLR1 and TLR2 are unusual
members of the ‘‘typical’’ subfamily of the LRR superfam-
ily (Bell et al., 2005; Choe et al., 2005; Kim et al., 2007b).
Typical subfamily LRR proteins have characteristic horse-
shoe-like structures whose concave surfaces are formed
by parallel b strands and whose convex surfaces are
formed by loops and 310 helices (Kajava, 1998; Kobe
and Kajava, 2001). The parallel b sheet of the typical sub-
family member has uniform twist angles and radii through-
out the entire protein. Unlike other typical family members
but like TLR4, the ectodomain of TLR2 can be split into
three distinctive subdomains: N-terminal, central, and C-
terminal subdomains with unique b sheet conformations
(Figure 2). The N-terminal domain contains the LRRNT
and 14 LRR motifs (Figure 3) and its structure agreesCell 1well with the consensus structure of the typical subfamily:
the length of LRRmodules varies little around a value of 24
amino acid residues, and the structurally important aspar-
agine ladder and phenylalanine spine are conserved. In
contrast, the central and C-terminal domains differ con-
siderably from the standard structure: the lengths of their
LRR modules range from 20 to 30 amino acids and their
b sheet conformations deviate significantly from those of
the standard LRRs. Both the asparagine ladder and the
phenylalanine spine are absent from the central domain,
and this may be responsible for its unusual b sheet confor-
mation, which differs substantially from the standard
values of the typical subfamily (Figure 3). The three-
domain architecture found in TLR2 and TLR4 is also pre-
served in TLR1. However, the b sheet conformations of
its central and C-terminal domains differ substantially,
and neither the TLR2 nor 4 structure can be superimposed
on that of TLR1 (Figure S1).
Ligand-Binding Sites in TLR1 and TLR2
The lipopeptide-binding site of TLR2 is found in a highly
unusual region. LRR family proteins typically have their li-
gand-binding sites located in the concave surfaces of the30, 1071–1082, September 21, 2007 ª2007 Elsevier Inc. 1073
Figure 3. Structure-Based Sequence Alignment of TLR1, 2, and 6
TLR1, TLR2, and TLR6 sequences are aligned based on their structures. Conserved leucines, residues in the asparagine ladder, and residues in the
phenylalanine spine are written in red, green, and blue, respectively. The positions of a helices are indicated by coils above the sequences and
labeled. The positions of the b strands are shown as arrows above the consensus pattern. Residues in the TLR ectodomains but not included in
the crystallized proteins are written in gray.horseshoe-like structures (Kim et al., 2007a; Pancer and
Cooper, 2006). Surprisingly, in TLR2, the convex region
formed at the border of the central and C-terminal do-
mains opens into a crevice that is connected to a large in-
ternal pocket (Figures 2 and 4A); the two ester-bound lipid
chains are inserted into the TLR2 pocket in extended con-
formation, and the amide-bound lipid chain and peptide
head group are exposed to the outside of the pocket,1074 Cell 130, 1071–1082, September 21, 2007 ª2007 Elsevierinteracting with TLR1 and hydrophilic interfacial residues
(Figures 4A and 4B). The surface of the internal pocket is
completely lined with hydrophobic residues from LRR
modules 912. The two ester-bound lipid chains occupy
over 90% of the total solvent-accessible volume of the
pocket (Figure 4C), and the remaining 10% of the pocket
may permit minor structural variation of the lipopeptide
ligands.Inc.
The lipid-binding channel of TLR1 is located in the same
region as that of TLR2, in the domain interface between
the central and C-terminal domains (Figures 2, 3, and
4A). The surface of the TLR1 channel is completely lined
with hydrophobic residues from LRR modules 912. The
volume of the channel is 400 A˚3, which is approximately
one quarter that of the TLR2 pocket, and the amide-bound
palmitoyl chain occupies almost all of the available space
in the channel (Figure 4C).
The conserved cysteinyl group and glycerol backbone
of the lipopeptide is located in the narrow opening formed
where the TLR1 and TLR2 pockets join. Their positions are
partially fixed by three strong hydrogen bonds: between
the backbone nitrogen of Phe349 and a carbonyl oxygen
Figure 4. The Lipopeptide-Binding Site of the Human TLR1-
TLR2 Complex
(A) TLR1 and TLR2 residues involved in Pam3CSK4 binding are drawn
in green and blue, respectively. The hydrogen bonds are shown by
broken red lines. Carbons, nitrogens, oxygens, and a sulfur of the
Pam3CSK4 are colored in orange, blue, red, and green, respectively.
The H3 helix is drawn as a coil for clarity. I319’ of TLR1 is hidden behind
the H30 helix.
(B) Chemical structure of Pam3CSK4. Residues interacting with
Pam3CSK4 are labeled. Hydrogen bonds are drawn with broken red
lines.
(C) The shape of the Pam3CSK4-binding pocket is shown in mesh. Mo-
lecular surfaces that belong to TLR1 and TLR2 are drawn in green and
blue, respectively. Pam3CSK4 is shown as a space-filling model.Cell 1of the lipopeptide, between the backbone oxygen of
Gly313’ and backbone nitrogen of Lys3’’ in the lipopep-
tide, and between the side chain of Gln316’ and the amide
oxygen in the lipopeptide (Figures 4A and 4B). Single
apostrophes are used for the TLR1 residues and double
apostrophes for the peptide residues of the ligand to dif-
ferentiate them from those of TLR2 throughout this article.
Cys1’’, the first amino acid residue of the lipopeptide, fits
tightly into the ligand-binding site of the complex. Cys1’’ is
completely conserved in all bacterial lipoproteins. The
small amino acids, serine and glycine, are preferred in
the second amino acid position of bacterial lipoproteins.
Ser2’’, the second amino acid residue of Pam3CSK4, is lo-
cated in the narrow neck region of the pocket. Therefore,
amino acids with bigger side chains may collide with TLR1
or TLR2 residues. The side chains of the four lysine resi-
dues of Pam3CSK4 have only limited interactions with
TLR1 or TLR2 except for a hydrogen bond of Lys4’’ with
Asn294 of TLR2, which is consistent with their low
sequenceconservation in thebacterial lipoproteins (Madan
Babu and Sankaran, 2002).
Omueti et al. reported, on the basis of domain-switching
experiments between TLR1 and TLR6, that the LRR912
modules of TLR1 play crucial roles in lipopeptide recogni-
tion (Omueti et al., 2005). These modules constitute the
critical portion of the central domain and form the lipid-
binding channel in TLR1 (Figure 3). Therefore changes in
these modules should have significant effects on the li-
gand-binding activity of TLR1. Furthermore, Meng et al.
reported, based on deletion mutagenesis experiments,
that the N-terminal seven LRR modules of TLR2 are not
necessary for Pam2CSK4 and Pam3CSK4 signaling
(Meng et al., 2003). The N-terminal LRR modules deleted
contained neither the ligand-binding nor the dimerization
region of TLR2. Therefore, these mutagenesis results are
consistent with and support our structural analysis of the
TLR1 and 2 complex. The same laboratory has shown
that the species-specific response to tri-lauroylated lipo-
peptide is mediated by the LRR710 modules of TLR2,
suggesting that this region interacts with the lipopeptide
ligands (Grabiec et al., 2004). Our structure shows that
the LRR710 subdomain overlaps with the ligand-binding
pocket of TLR2.
The Dimerization Interface between
TLR1 and TLR2
The Pam3CSK4 ligand is indispensable for heterodimeri-
zation of the ectodomains of TLR1 and TLR2 as it bridges
the two proteins through its three lipid chains. In addition
to the lipid chain interactions, TLR1 and TLR2 amino acids
form hydrophobic, hydrogen-bonding, and ionic interac-
tions, further stabilizing the protein heterodimer (Figure 5).
The dimer interface has approximate dimensions of 850
A˚2 and a nearly circular shape with the bound lipopeptide
chain in the center. Like other strong protein-protein inter-
action interfaces, the TLR1-TLR2 interface has a small hy-
drophobic core in the center surrounded by hydrogen-
bonding and ionic interactions in the periphery (Figure 5).30, 1071–1082, September 21, 2007 ª2007 Elsevier Inc. 1075
Figure 5. Heterodimeric Interface of
TLR1-TLR2
(A) Structure of the residues involved in the di-
mer interface. The TLR1 and 2 interface is split
and rotated by 90 degrees. Part of the lipid
chains and the cysteine residue of the bound
Pam3CSK4 are shown and its carbons, oxy-
gens, and a sulfur are colored in orange, red,
and green, respectively. Structure of TLR1 res-
idues involved in the hydrophobic core of the
interface are colored in light green, and resi-
dues involved in hydrogen or ionic bonds in
dark green. TLR2 residues involved in the hy-
drophobic core of the interface are colored
cyan, and residues involved in hydrogen or
ionic bonds in blue. The Pro315’ of TLR1
shows polymorphic variation and is labeled in
red. (B) Interacting residues in the TLR1 and
TLR2 interface are linked by broken lines.Our structural observations are supported by previous
biochemical and cell biological results. Omueti et al. re-
ported that a polymorphic variant of TLR1 with Pro315’
changed to leucine was greatly impaired in responses to
Pam3CSK4 (Omueti et al., 2007). Furthermore an antibody
that recognized the Pro315’ region inhibited TLR1 sig-
naling. In our crystal structure, Pro315’ is part of the
hydrophobic core of the dimer interface (Figure 5A), and
its alterationmay affect lipopeptide signaling by disrupting
TLR1-TLR2 dimerization.
Structures of the Mouse TLR2-Pam3CSK4
and TLR2-Pam2CSK4 Complexes
In order to study the structural changes of TLR2 induced
by TLR1 binding, and differences in structure between
human and mouse TLR2, we crystallized mouse TLR2 in
complex with Pam3CSK4 and Pam2CSK4 lipopeptides
and determined their structures. As with human TLR2,
we produced serial deletions of mouse TLR2 fused with
hagfish VLRB.61 fragments using the Hybrid LRR tech-
nique (Table S1). We managed to produce and crystallize
the mT2V6 hybrid with 82 C-terminal amino acids of the
mouse TLR2 ectodomain replacedwith a fragment of hag-
fish VLRB.61 (Figure 1) in a complex with both Pam3CSK4
and Pam2CSK4. The purified mT2V6 hybrid protein eluted
as a monomer on the gel filtration chromatography (data
not shown) and was crystallized as a monomer together1076 Cell 130, 1071–1082, September 21, 2007 ª2007 Elsevierwith the lipopeptide, indicating that binding of the ligand
did not induce oligomerization of the protein.
As expected from their 68% sequence identity, the
structures of mouse TLR2 and human TLR2 are highly ho-
mologous. The rms difference of the backbone atoms is
1.1 A˚ (Figure S2). The largest structural change is in the
flexible loops of the LRR10 and 11 modules. This change
is unlikely to be due to the sequence differences between
the central domains of the TLR2 because the sequences
are highly homologous and the residues with clear struc-
tural roles are strictly conserved (Figure 3). Instead, the
binding of TLR1 in the TLR1-TLR2 complex appears to ini-
tiate structural changes of LRR10 and 11 of TLR2 that ren-
der the lipid-binding pocket of TLR2 more compact. Al-
though Pam2CSK4 does not contain the amide-bound
lipid chain, Pam3CSK4 and Pam2CSK4 bind to the lipid-
binding pocket of mouse TLR2 in practically identical
fashion: the two ester-bound lipid chains are inserted
into the lipid-binding pocket, and the amide-bound lipid
chain and peptide chain are exposed to the solvent with-
out interacting significantly except for a hydrogen bond
between the backbone nitrogen of Phe349 and a carbonyl
oxygen of the lipid chains of Pam3CSK4 and Pam2CSK4
(Figure 6A).
Although the backbone structures of the human and
mouse TLR2s are practically identical, their side chains in
the lipid-binding pocket differ significantly in sequenceInc.
Figure 6. Structure of the Mouse TLR2-
Pam3CSK4 Complex
(A) The structure of mouse TLR2 in the mT2V6
hybrid. Carbons, oxygens, and a sulfur in
Pam3CSK4 are colored orange, red, and green,
respectively. The peptide and lipid chains
shown by broken lines are very flexible and
not visible in the electron density map. The
H3 helix is shown as a coil for clarity.
(B) The shape of the lipid-binding pocket of
mouse TLR2. BoundPam3CSK4 is represented
by a space-filling model. The peptide and
amide-bound lipid chains not visible in the
electron density map are modeled from their
structures in the hTLR1-hTLR2-lipopeptide
complex (Figure 4) and are drawn with a dotted
surface.
(C) Structural differences between the lipid-
binding pockets of human and mouse TLR2s.
The side chains of the residues that differ sig-
nificantly are shown. The human and mouse
TLR2 structures are taken from those of the
hTLR1-hTLR2-Pam3CSK4 and the mTLR2-
Pam3CSK4 complexes. Substantial structural
changes aremarkedwith broken green arrows.and structure. These changes cause the shape of the lipid-
binding pocket to differ substantially between mouse and
human TLR2s (Figure 6B). Grabiec et al. reported subtle
differences in the ligand specificities of mouse and human
TLR2 (Grabiec et al., 2004). For example, they found that
a lipopeptide with shorter lipid chains, tri-lauroylated
Lau3CSK4, could activate mouse TLR2 but not human
TLR2. In our crystal structures, the two palmitoyl chains
of Pam3CSK4 bound to human TLR2 are in an extended
conformation whereas those bound to mouse TLR2 are
bent at the eleventh and the twelfth carbons because the
lipid-binding pocket in mouse TLR2 is shorter (Figure 6B).
Therefore the shorter lauryl groupsmay still bind efficiently
to mouse TLR2 but not to human TLR2. Sequence differ-
ences between the human and mouse TLR2s, including
Thr335 to leucine, Pro306 to leucine, and Leu266 to phe-
nylalanine, appear to be responsible for the changed
shape of the lipid-binding pocket (Figure 6C).
DISCUSSION
Structural Comparison of TLR Family Proteins
The human TLR family can be divided into six subfamilies
by phylogenetic analysis (Matsushima et al., 2007; Roach
et al., 2005). Until now, four structures belonging to three
subfamilies, including those of TLR1 and TLR2 in this
report, have been determined (Bell et al., 2005; Choe
et al., 2005; Kim et al., 2007b). Although the overall horse-
shoe-like shape is conserved, none of these TLR family
proteins can be superimposed except for their N-terminalCell 1domains (Figure S1). TLR1, 2, and 4 but not TLR3 have an
unusual three-domain architecture with N-terminal, cen-
tral, and C-terminal domains. Less sequence conserva-
tion and the absence of the asparagine ladder appear to
be strong indicators of the presence of the central domain
(Figure 3; see also Kim et al., 2007b). The asparagine lad-
der is formed by a continuous network of hydrogen bonds
between conserved asparagines and neighboring back-
bone oxygens so that its disruption will have a significant
impact on the overall protein conformation (Kajava, 1998;
Kim et al., 2007a; Kobe and Kajava, 2001). The unusual
structural properties of the central domains also have im-
portant effects on protein function: they are crucial for cor-
eceptor binding of TLR4 and ligand binding and receptor
dimerization of TLR1 and 2 (Figure 2; see also Kim et al.,
2007b). Standard LRR family proteins use their concave
surfaces for ligand binding, probably because they pro-
vide larger surfaces ideal for binding macromolecular li-
gands (Kim et al., 2007a; Pancer and Cooper, 2006). How-
ever, efficient binding of small-molecule ligands such as
lipopeptides requires pocket-like structures, and the
sharp structural transition at the boundary between the
central and C-terminal domainsmay be essential for form-
ing such a ligand-binding pocket. Structure of the lipopep-
tide-binding pocket in TLR2 is reminiscent of that of the li-
popolysaccharide-binding pocket in CD14 (Kim et al.,
2005). The TLR2 pocket is formed at the domain boundary
between the central and C-terminal domains whereas the
CD14 pocket is formed at the boundary of the LRRNT and
LRR modules. In both proteins, the flexible loops in the30, 1071–1082, September 21, 2007 ª2007 Elsevier Inc. 1077
convex surfaces open a crevice that is connected to
a large internal pocket.
Model of the TLR2 and TLR6 Heterodimer
It has been reported that tri-acylation of lipopeptides is re-
quired for signaling by the TLR1-TLR2 complex whereas
di-acylation is required for signaling by the TLR2-TLR6
complex (Alexopoulou et al., 2002; Morr et al., 2002; Ozin-
sky et al., 2000; Takeuchi et al., 2001, 2002). To seek
a structural explanation for the ligand specificity of the
two TLR2 complexes, we modeled the structure of TLR6
with an automatic homology modeling server using the
TLR1 structure as template (Tosatto, 2005). TLR1 and
TLR6 share 56% sequence identity with only a single
two-amino acid gap (Figure 3). Therefore the two proteins
should have highly homologous structures, and homology
modeling is straightforward. The analysis suggests that
TLR6 does not contain the lipid-binding channel; there
are quite a few differences in amino acid sequence be-
tween TLR1 and TLR6 in the regionwhere the lipid-binding
channel of TLR1 is located (Figure S3A). Among these, the
changes of Met338’ and Leu360’ to phenylalanines ap-
pear to have themost significant effect. Leu360’ is located
behind Met338’, which is directly involved in the formation
of the TLR1 channel, and the simultaneous changes of
both these residues to bulky phenylalanines appear to
block the potential lipid channel in TLR6. Therefore the
amide-bound lipid chain of the tri-acylated lipopeptide
may not be able to interact with TLR6 so as to initiate sig-
naling through the TLR2 and TLR6 complex. Furthermore,
there are substantial changes in the dimerization interface
that may promote heterodimerization of TLR2 and 6 with-
out the amide-bound lipid chain (Figure S3B). Since di-
acylated lipopeptides do not have amide-bound lipid
chains that can bridge TLR2 and 6, their interfacial resi-
dues and the head group of the ligand must play a more
important role in the TLR2 and 6 complex than in the
TLR1 and 2 complex. Therefore, the structure of the po-
tential TLR2 and 6 complex may resemble that of the re-
cently published CD1d and NKT T cell receptor complex
(Borg et al., 2007). In the latter, the two lipid chains of
the ligand bind to a large hydrophobic pocket in CD1d
and the hydrophilic head group of the ligand promotes
CD1d and TCR interaction by forming several crucial
hydrogen bonds with the surface residues of TCR.
Some ligands, including synthetic variant lipopeptides,
appear to activate TLR2 signaling independently of both
TLR1 and TLR6 (Buwitt-Beckmann et al., 2006). To explain
this, homodimerization of TLR2 has been proposed. In our
experiments, neither binding of Pam3CSK4 nor that of
Pam2CSK4 induced homodimerization of the human and
mouse TLR2 hybrids, hT2V9 and mT2V6. However, this
does not exclude the possibility that these ligands induce
homodimerization of the full-length TLR2 including the
transmembrane and intracellular domains. In either case,
our data demonstrate that the TLR2 homodimer, if it
exists, must have a dimeric structure different from that
of the TLR1 and 2 heterodimer.1078 Cell 130, 1071–1082, September 21, 2007 ª2007 ElsevieNonlipopeptide Ligands of TLR2
TLR2 binds a wider range of ligands than other proteins in
the TLR family. In addition to the lipopeptides/lipopro-
teins, a variety of compounds including lipoteichoic acids,
lipoarabinomannan, and zymosan have been shown to
signal through TLR2 complexes (Akira and Takeda,
2004). The formation of combinatorial binding sites by se-
lection of TLR1 or TLR6 as the dimerization partner ex-
plains at least in part the broad ligand specificity. Lipotei-
choic acids (LTAs) have been shown to be potent
activators of innate immune responses via TLR2, although
there is some controversy concerning their preparation
and activity (Deininger et al., 2003; Hashimoto et al.,
2007; Morath et al., 2005). LTAs have clear structural ho-
mology with di-acylated lipopeptides. They have two lipid
chains attached to the glycerol backbone that is con-
nected to a hydrophilic glycerophosphate or phosphory-
lated ribitol tetrasaccharide polymer chain. The structural
homology predicts that LTAs bind to TLR2 in a fashion
similar to that of lipopeptides. Since TLR2 does not con-
tain other hydrophobic pockets large enough for binding
the long lipid chains of LTAs, and since both Pam3CSK4
and Pam2CSK4, with different chemical structures, bind
to the same site in a nearly identical structure, the two lipid
chains of LTAs are likely inserted into the Pam3CSK4-
binding pocket in TLR2. In this binding mode, the hydro-
philic glycerophosphate chain will be exposed to solvent
or may interact with TLR6 or another binding partner of
TLR2.
Roles of the Accessory Proteins
CD14 and CD36 have been shown to enhance signaling
through TLR2 complexes in response to several ligands.
CD14 is an LRR family protein that has a hydrophobic
pocket for binding amphipathic ligands such as LPS and
lipopeptides. It has been proposed to catalyze transfer
of lipopeptide ligands to TLR2 complexes (Manukyan
et al., 2005; Nakata et al., 2006; Sellati et al., 1998). Al-
though CD14 and TLR proteins do not form stable com-
plexes, they are located close together in the plasma
membrane for efficient functioning (Manukyan et al.,
2005; Nakata et al., 2006). Thus, CD14 appears to form
transient complexes with TLR proteins and transfers
monomerized ligands to them. Regions of CD14 responsi-
ble for TLR interaction were mapped near the ligand-
binding pocket (Iwaki et al., 2005; Nakata et al., 2006).
However, CD14 interaction sites in TLR2 or TLR4 have
not yet been studied. Future biochemical and structural
research is required to elucidate TLR interaction and
ligand transfer mechanisms of CD14.
CD36 is necessary for efficient signaling by R-MALP
and lipoteichoic acid but not by S-MALP, Pam2CSK4,
Pam3CSK4, and zymosan (Hoebe et al., 2005). It is not
clear if CD36 exerts its effect through physical interaction
or through indirect functional interaction with TLR2. How-
ever, since TLR2 requires two lipid chains for efficient
binding, and CD36 also requires lipid chains for binding,
it is very unlikely that R-MALP or lipoteichoic acid withr Inc.
Figure 7. Model of the Ligand-Induced
Heterodimer of Full-Length TLR1 and
TLR2
The cell membrane is shown schematically in
orange, and connecting linker regions are rep-
resented by broken lines. The structure of the
heterodimeric TIR domain is drawn as pro-
posed by Gautam et al. using PDB coordinates
1FYV and 1FYW (Gautam et al., 2006; Xu et al.,
2000). Distance between the C termini of the
TLR1 and 2 ectodomains is approximately 40
A˚. Diameter of the TIR dimer is estimated to
be 50 A˚. Structure of the pre-existing dimer is
unknown.two lipid chains can bridge the formation of complexes of
TLR2 and CD36 as shown in our TLR1 and 2 complex.
Ligand-Induced Dimerization and Activation
of TLR1 and 2
We have reported here that binding of lipopeptide induces
heterodimerization of the ectodomains of TLR1 and TLR2.
Full-length TLR proteins in the lipid membrane have been
shown to form homotypic or heterotypic multimers with-
out bound ligands (Akira and Takeda, 2004; Latz et al.,
2007; Ozinsky et al., 2000; Triantafilou et al., 2006). There-
fore binding of lipopeptides to the TLR1 and 2 ectodo-
mains appears to induce rearrangement of these pre-
formed and weakly bound multimers to initiate signaling
(Figure 7). It has been suggested that homo- or heteromul-
timerization of TLRs activates signaling by inducing multi-
merization of their intracellular TIR domains (O’Neill and
Bowie, 2007). Our crystal structure supports this hypoth-
esis in that ligand-induced heterodimerization of the
TLR1 and TLR2 ectodomains brings their C termini close
to one another, which may promote heterodimerization
of their intracellular TIR domains and so provide a platform
for recruitment of adaptor proteins (Figure 7). Our model is
consistent with recent FRET/FRAP results that showed
that fluorescently labeled Pam3CSK4 bound to the TLR1
and TLR2 complex expressed on transfected HEK293
cells and the ligand binding reduced mobility of the
TLR2 complex presumably due to recruitment of intra-
cellular proteins (Manukyan et al., 2005).
The dimerization and activation mechanisms of other
TLR family proteins have been studied and several models
have been proposed. We have previously presented
a model of TLR4-MD-2 dimerization induced by binding
of the agonistic ligand, LPS (Kim et al., 2007b). In this
model, binding of LPS induces a conformational change
in the structure ofMD-2 that promotes binding of a second
TLR4 to MD-2 and therefore induces formation of the
TLR4-MD-2 heterotetramer. The proposed model of the
TLR4-MD-2 heterotetramer is similar to the structure of
the TLR1 and 2 heterodimer presented in this article ex-
cept that the coreceptor MD-2, not TLR4, is responsible
for ligand binding. Latz et al. recently proposed an activa-
tion mechanism of TLR9 on the basis of fluorescence andCell 1crosslinking assays (Latz et al., 2007). They showed that
TLR9 exists as a preformed homodimer without bound li-
gand, and that binding of an agonistic ligand but not of an
antagonistic ligand brings the intracellular TIR domains
closer for dimerization. Their model of the TLR9 homo-
dimer closely resembles our model of the TLR1-TLR2 het-
erodimer. Choe et al. have proposed a model of the TLR3
dimer induced by binding of dsRNA binding (Choe et al.,
2005). They suggest that the crystallographic dimer of
ligand-unbound TLR3 resembles the TLR3 dimer with
bound dsRNA. Although their model may be criticized
for a lack of experimental support and several unlikely
structural features (Kirk and Bazan, 2005), it is similar to
other proposed TLR dimer models in the sense that the
C termini of the two ectodomains converge in the middle.
Further structural research is required to confirm if the
ectodomains of these TLR proteins indeed form similar
hetero- or homodimeric structures in response to binding
of agonists.
In conclusion, we report the crystal structure of the
TLR1-TLR2-tri-acylated lipopeptide complex. This gives
the first high-resolution view of a ligand-induced multimer
of TLR family proteins and provides a structural explana-
tion for why both TLR1 and 2 are required for tri-acylated
lipopeptide binding and signaling. Based on the structure,
we propose that ligand-induced dimerization of extracel-
lular domains brings the two intracellular TIR domains
into close proximity and initiates signaling.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
The TLR1/2 and VLR hybrids (Tables S1–S4) were cloned between the
BamH1 and Not1 or the XbaI and Not1 sites in the pVL1393 baculovi-
rus vector (BD Biosciences) (Figure S4). The Fc domain of human IgG1
was cloned between the NotI and BglII sites of the pVL1393 vector,
and a thrombin cleavage site was introduced between the hybrid
genes and the Fc tag. All Fc-tagged TLR-VLR hybrids were expressed
in Hi5 insect cells (Invitrogen) and purified by protein A agarose chro-
matography (Peptron). After cleavage by thrombin to remove the
Fc tag, all the TLR2-VLR hybrid proteins except the hT2V2 hybrid
were further purified by HiTrap Q (GE Healthcare) anion exchange
and Superdex-200 gel filtration chromatography (GE Healthcare).
The hT2V2 hybrid and all TLR1-VLR hybrid proteins were purified by
HiTrap SP (GE Healthcare) cation exchange and Superdex-200 gel
filtration chromatography after thrombin cleavage.30, 1071–1082, September 21, 2007 ª2007 Elsevier Inc. 1079
Binding of Lipopeptides to the Mouse TLR2
and Human TLR1-TLR2 Complex
For complex formation, a synthetic R-isomer of Pam3CSK4 (EMC Mi-
crocollections GmbH) was incubated with 5 mg/ml of purified mT2V6
at room temperature for 3 hr in a buffer containing 20 mM Tris HCl
(pH 8.0) and 200 mM NaCl. Ligand binding was monitored by band
shifting on native-PAGE. The molar ratio of Pam3CSK4 to the protein
was maintained at 3:1. The mT2V6-Pam3CSK4 complex was crystal-
lized without further purification. The R-isomeric Pam2CSK4 (EMC Mi-
crocollections GmbH) andmT2V6 complex was produced by the same
method, and the hT1V8-hT2V9-Pam3CSK4 complex was produced by
successive binding of hT1V8 and hT2V9. First, hT2V9 and Pam3CSK4
were incubated at room temperature for 2 hr in a buffer containing
20 mM Tris HCl (pH 8.0) and 200 mM NaCl. Then, hT1V8 was added
to the reaction mixture, which was incubated at 37C for an additional
2 hr. The concentrations of hT1V8 and hT2V9were 2.5mg/ml each, and
the molar ratio of Pam3CSK4 to the proteins was kept at 5:1. It was
purified by Superdex-200 gel filtration chromatography to remove
unbound TLRs and Pam3CSK4 before crystallization.
Crystallization and Data Collection
All mT2V6-Pam2CSK4, mT2V6-Pam3CSK4, hT1V8-hT2V9-Pam3CSK4,
and hT2V2 were crystallized at 23
C by the hanging-drop vapor
diffusion method. Crystals of the mT2V6-Pam3CSK4 and mT2V6-
Pam2CSK4 complexes were obtained bymixing 1 ml of protein solution
and 1 ml of reservoir solution containing 0.2 M ammonium sulfate,
0.1 M Tris-HCl (pH 8.5), and 34% PEG1000. For data collection, crys-
tals were transferred to a cryo-protective solution containing 45%
PEG1000, 0.2 M ammonium sulfate, and 0.1 M Tris-HCl (pH 8.5).
The hT1V8-hT2V9-Pam3CSK4 complex was crystallized using a solu-
tion containing 0.2 M sodium citrate, 20% PEG3350 (Hampton Re-
search). The cryo-protective solution has 30% glycerol added to the
crystallization solution. Crystals of the hT2V2 were crystallized using
a solution containing 0.1 M Tris-HCl (pH 8.5), 28% PEG2000. The
cryo-protective solution has 45% PEG2000 and 0.1 M Tris-HCl
(pH 8.5). All crystals were flash-frozen in boiling liquid nitrogen at
170C. Diffraction data were collected at the 4A beam line of the
Pohang Accelerator Laboratory, the BL41XU beam line of SPring-8,
the ID14-2 beam line of ESRF, and the BL5.0.1 beam line of ALS.
The HKL2000 package (HKL research) and the MOSFLM/SCALA
programs (Winn, 2003) were used to index, integrate, and scale the
diffraction data.
Structure Determination
The initial phases were calculated by molecular replacement using the
program PHASER (McCoy et al., 2005). Crystallographic statistics and
the search probes used for the molecular replacement calculations are
summarized in Table S5. The atomic models were built by iterative
modeling and refinement using the program O and CNS (Bru¨nger
et al., 1998; Jones et al., 1991). The atomic model of Pam3CSK4 was
built into a strong and continuous electron density that was found in
the TLR1 and TLR2 pockets (Figure S5). The residues from 241 to
247 of hT2V2 were not visible in the electron density map and not
included in the final atomic model. No nonglycine residues are found
in the disallowed region of Ramachandran plot.
Homology Modeling
Human TLR1 and TLR6 sequenceswith Swiss-Prot codesQ15399 and
Q9Y2C9, respectively, were aligned using the ClustalW program
(Chenna et al., 2003) and submitted to the HOMER modeling server
with ‘‘side chain placement’’ option (Tosatto, 2005). The atomic
coordinates of the hT1V8 hybrid were used as the template.
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